Early work on bone marrow cells to heal fragile hearts showed only modest effects. But new research looks at different types of stem cells. 'We're trying to tear pages out of nature's playbook,' says a Chicago cardiologist.
It's one of the most vexing problems in medical science: How can you mend a broken heart?
A decade ago, researchers and cardiologists thought they had found an answer in stem cells. These powerful cells lurk throughout the body, repairing and maintaining tissues as needed. In the laboratory, scientists can transform them into heart cells. When implanted in animals, they grow into new heart tissue too.
So it was with high hopes that researchers transfused stem cells into patients suffering from heart failure — people whose hearts, weakened by heart attacks or other conditions, no longer pumped enough blood through their bodies. But in clinical trials, the effects have been modest. Stem cells appeared to help, but not as much as doctors had hoped — and not in the ways they had expected.
Now those early results are pointing researchers toward other types of stem cells that may be better suited to help repair cardiac muscle. With 5 million Americans currently suffering from heart failure — and their ranks sure to grow as 76 million baby boomers march into old age — cardiologists are counting on breakthroughs in stem cell therapy.
"We're trying to tear pages out of nature's playbook," says Dr. Douglas W. Losordo, director of the program in Cardiovascular Regenerative Medicine at Northwestern Memorial Hospital in Chicago.
Hearts and bones
As the era of regenerative medicine dawned, stem cells seemed a perfect candidate to rebuild damaged hearts.
The stem cells in bone marrow were particularly tantalizing. Long used to rebuild the immune systems of cancer patients, scientists discovered that they also have the capacity to grow into heart muscle, blood vessels and other tissues — at least under certain laboratory conditions. Bone marrow is easy to extract from patients, and the therapeutic cells derived from it are a perfect genetic match for patients, greatly reducing the risk of tissue rejection.
Researchers and clinicians imagined using stem cells to undo the damage caused by a heart attack. In just a few minutes, a blockage in an artery can cut off oxygen to the heart, killing as many as a billion cells. The cells, for the most part, don't grow back. Instead, what remains is scar tissue and a weakened circulatory system.
Heart attacks aren't nearly as deadly as they used to be — more than 4 out of 5 heart attack victims are still alive after one year, according to a study last month in the American Journal of Medicine.
But the damage caused by a heart attack can result in heart failure — and patients diagnosed with heart failure have an average life expectancy of less than five years, according to Dr. Chuck Murry, director of the Center for Cardiovascular Biology at the University of Washington in Seattle.
"It's deadlier than breast cancer," Murry says.
That helps explain the enthusiasm for clinical trials involving stem cells from bone marrow. From 2002 to 2006 alone, there were at least 18 randomized controlled studies involving nearly 1,000 patients.
"Everyone started putting bone marrow in the heart," says Christine Mummery, a researcher at Leiden University Medical Center in the Netherlands, who has studied how to turn stem cells into heart muscle cells called cardiomyocytes.
But the results, she says, were a mixed bag. The treatment appeared to be safe, but patients had only transient improvement.
"People went from being very sick to a little less sick," Mummery says.
There is a silver lining: Even stem cells that don't grow into new heart cells seem to help patients in other ways. As the bone marrow transplant trials continue, researchers are trying to sort it all out.
"It's a little bit mysterious," says Dr. Eduardo Marbán, director of the Cedars-Sinai Heart Institute in Los Angeles.
Marbán, like many, believes the improvements came about because transplanted cells secreted chemicals that boosted heart function — not because any new heart tissue grew. The "stem cells are working mostly by raising an alarm to resident cardiac stem cells. They seem to work indirectly."
A decade ago, researchers and cardiologists thought they had found an answer in stem cells. These powerful cells lurk throughout the body, repairing and maintaining tissues as needed. In the laboratory, scientists can transform them into heart cells. When implanted in animals, they grow into new heart tissue too.
So it was with high hopes that researchers transfused stem cells into patients suffering from heart failure — people whose hearts, weakened by heart attacks or other conditions, no longer pumped enough blood through their bodies. But in clinical trials, the effects have been modest. Stem cells appeared to help, but not as much as doctors had hoped — and not in the ways they had expected.
Now those early results are pointing researchers toward other types of stem cells that may be better suited to help repair cardiac muscle. With 5 million Americans currently suffering from heart failure — and their ranks sure to grow as 76 million baby boomers march into old age — cardiologists are counting on breakthroughs in stem cell therapy.
"We're trying to tear pages out of nature's playbook," says Dr. Douglas W. Losordo, director of the program in Cardiovascular Regenerative Medicine at Northwestern Memorial Hospital in Chicago.
Hearts and bones
As the era of regenerative medicine dawned, stem cells seemed a perfect candidate to rebuild damaged hearts.
The stem cells in bone marrow were particularly tantalizing. Long used to rebuild the immune systems of cancer patients, scientists discovered that they also have the capacity to grow into heart muscle, blood vessels and other tissues — at least under certain laboratory conditions. Bone marrow is easy to extract from patients, and the therapeutic cells derived from it are a perfect genetic match for patients, greatly reducing the risk of tissue rejection.
Researchers and clinicians imagined using stem cells to undo the damage caused by a heart attack. In just a few minutes, a blockage in an artery can cut off oxygen to the heart, killing as many as a billion cells. The cells, for the most part, don't grow back. Instead, what remains is scar tissue and a weakened circulatory system.
Heart attacks aren't nearly as deadly as they used to be — more than 4 out of 5 heart attack victims are still alive after one year, according to a study last month in the American Journal of Medicine.
But the damage caused by a heart attack can result in heart failure — and patients diagnosed with heart failure have an average life expectancy of less than five years, according to Dr. Chuck Murry, director of the Center for Cardiovascular Biology at the University of Washington in Seattle.
"It's deadlier than breast cancer," Murry says.
That helps explain the enthusiasm for clinical trials involving stem cells from bone marrow. From 2002 to 2006 alone, there were at least 18 randomized controlled studies involving nearly 1,000 patients.
"Everyone started putting bone marrow in the heart," says Christine Mummery, a researcher at Leiden University Medical Center in the Netherlands, who has studied how to turn stem cells into heart muscle cells called cardiomyocytes.
But the results, she says, were a mixed bag. The treatment appeared to be safe, but patients had only transient improvement.
"People went from being very sick to a little less sick," Mummery says.
There is a silver lining: Even stem cells that don't grow into new heart cells seem to help patients in other ways. As the bone marrow transplant trials continue, researchers are trying to sort it all out.
"It's a little bit mysterious," says Dr. Eduardo Marbán, director of the Cedars-Sinai Heart Institute in Los Angeles.
Marbán, like many, believes the improvements came about because transplanted cells secreted chemicals that boosted heart function — not because any new heart tissue grew. The "stem cells are working mostly by raising an alarm to resident cardiac stem cells. They seem to work indirectly."